Changing Landscape of NSCLC with Targeted Therapies and Immunotherapy

Target Audience
This activity is designed to meet the educational needs of medical oncologists, thoracic surgeons, radiation oncologists, nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment of non-small cell lung cancer (NSCLC) patients.

Program Overview
This activity will cover topics on the diagnosis, treatment, and management of patients with non-small cell lung cancer.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Select first-line therapy for patients with EGFR-, EGFR T790M-positive, and ALK-positive NSCLC based on clinical factors and molecular subtyping
Outline mechanisms of acquired resistance to EGFR- EGFR T790M-TKI and ALK-positive therapy and selection of sequential treatment in these patients
Outline the optimal use of immune checkpoint inhibitors (ICIs) and combination approaches in NSCLC
Implement strategies to assess, recognize, and manage immune-related adverse events (IRAES) in patients treated with ICIs.